By law, Medicare Part D cannot cover drugs prescribed strictly for weight loss, which is why a GLP-1 may be covered for a Medicare patient with type 2 diabetes but not for obesity alone
Enhancement in the SREBP-1c/PPAR ratio, an indication that lipogenesis is higher than fatty acid oxidation, was found in obese patients with hepatic steatosis [16]
Because Ozempic is simply the brand name for semaglutide, this is the identical question to whether you can take Ozempic and retatrutide together same GLP-1 overlap, same answer
For those working towards weight loss, these medications promote a feeling of fullness and reduce overall appetite, leading to decreased caloric intake and sustainable weight management
A systematic review and meta-analysis published in 2025 suggested GLP-1s were not cost-effective in treating obesity without diabetes